Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual Meeting
Mercy BioAnalyticsMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting showing the performance of its Mercy Halo™ Ovarian Cancer screening test in a large cohort of asymptomatic, postmenopausal women.